Skip to content

Jekyll-Hyde MicroRNA Binding Variant Linked to Improved Outcome in Early-stage Colorectal Cancer

October 28, 2010
Bookmark and Share

• MicroRNA variant also predicts worse survival in later stages of cancer.
• Variant leads to ineffective regulation of KRAS.
• Another pathway may be regulating tumor growth.

PHILADELPHIA — A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

Researchers said they don’t know why this variant site, a microRNA binding site that should allow appropriate regulation of the KRAS gene, exhibited a Dr. Jekyll and Mr. Hyde duality. Further study could show that patients with this miRNA variant might benefit from therapy early-on to forestall aggressive tumor behavior.

“Our results suggested that patients with this variant have a good prognosis, but only in early stages. We need to make sure we identify them in an early stage before the cancer progresses,” said lead researcher Kim M. Smits, Ph.D., a molecular biologist and epidemiologist in the GROW-School for Oncology and Developmental Biology at Maastricht University Medical Center, in the Netherlands.

The binding site responds to a molecule that belongs to the lethal-7 (let-7) family of microRNAs that has been linked to control the KRAS gene, which, if unregulated or mutated, can lead to growth of colorectal cancers. But the “G” variant at this site has been shown to lead to poorly regulated KRAS because it does not allow appropriate binding of let-7 to the gene, thus leading to increased KRAS expression. The G variant has previously been associated with an increased risk of lung cancer in moderate smokers, increased risk of ovarian cancer, reduced survival among patients with oral cancers and reduced survival in late-stage colorectal cancer independent of KRAS mutations.

In this study, the researchers evaluated the effect the G variant had on early-stage colorectal cancer compared to the more common “wild type” T variant.

Researchers examined preserved tissue from 409 early-stage colorectal cancer patients who were part of the Netherlands Cohort Study from 1989 to 1994. Median survival was 7.6 years, but patients with the G variant had a 54 percent improved survival compared to patients with T variant. This survival benefit was enhanced if KRAS mutations were taken into account, Smits said.

“None of the patients with a KRAS mutation and the T variant died,” she said.

In later stages of the cancer, this survival advantage was reversed, which Smits said was unexpected.

“You would intuitively think that the G variant would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case,” said Smits.

Smits believes that in patients with the G variant, “KRAS control has been taken over by another, still unidentified pathway. These patients may be born with reduced KRAS control and I think the body has taken action on this, and another pathway controlling KRAS is overexpressed or activated to compensate for the imbalance.”

“This would explain why these patients have a good prognosis, even if KRAS has an activating mutation — KRAS is controlled by another pathway,” she said. “In late-stage patients, this alternative pathway might be impaired, thereby losing KRAS control.”

# # #

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.

Media Contact:
Jeremy Moore
(267) 646-0557
jeremy.moore@aacr.org
Loews Hotel, Phila., Oct. 27-30:
(267) 256-7172

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: